Edwin M. Horwitz, MD, PhD, Chairman of Pluristem's Scientific Advisory Board, President of the ISCT (International Society of Cell Therapy) and Director of Cell Therapy in the Division of Oncology / Blood & Marrow Transplantation at Children’s Hospital of Philadelphia stated: “Interestingly, the statistically significant improvement in the symptom of pain as measured by the Visual Analogue Score (VAS) suggests PLX cells may be effective therapy for other pain syndromes, such as the neuropathic pain associated with Herpes Zoster (shingles). Neuropathic pain includes an ischemic and inflammatory etiology. The previous announcement that PLX cells significantly improved the outcome in two different animal models of neuropathic pain, in addition to the significant VAS improvement in this study, suggests PLX cells may also be used as a potential pain therapy.”Safety Endpoints: -No significant unfavorable effects due to the administration of PLX-PAD occurred. One major amputation was reported in the PLX-PAD high dose group and was determined not to be related to the administration of PLX-PAD cells. This case represented 4.7% of all patients treated in this study and compares to historical data that indicates a 35-40% major amputation rate in CLI patients/yr. -None of the patients developed an anti-HLA antibody response and no specific anti-PLX HLA class-I or class-II antibodies were detected in the patients tested. This indicates PLX-PAD cells are immune competent and can be given to the patient “off-the-shelf” without a need for matching. -Immunological profiles demonstrated a rise in anti-inflammatory and angiogenic protein secretion post-dosing suggesting PLX-PAD cells function to deliver appropriate therapeutics proteins in response to the ischemic, inflammatory process of CLI. Efficacy Parameters: -Across all doses, 13 patients (62%) demonstrated an improvement in the ankle-brachial index (ABI), a measure of blood flow. Eleven patients receiving the intermediate dose demonstrated a statistically significant improvement from baseline (P=0.033).
-Across all doses, 13 patients (62%) demonstrated an improvement in the Transcutaneous Oxygen Pressure (TcPO2), a measure of tissue oxygenation. This improvement was statistically significant in the European study where the distribution of injections was higher (P=0.05).-Across all doses, 17 patients (81%) demonstrated an improvement in ABI, TBI or TcPO2. -Across all doses, 17 patients (81%) demonstrated a statistically significant improvement from baseline in the King’s College Score for Quality of Life (QoL) assessment (P< 0.001). Eleven patients receiving the intermediate doses demonstrated the best improvement from baseline in the QoL score (P< 0.001). -Across all doses, 15 patients (71%) demonstrated an improvement from baseline in the reduction of pain as measured by using the VAS. This improvement was statistically significant in the European study where the distribution of injections was higher (P=0.013). “The results of these trials provide a strong indication of the potential success of commercializing PLX-PAD,” said Zami Aberman, President, Chairman and CEO of Pluristem. “We have proven our PLX-PAD cells are safe and well tolerated when given intramuscularly as an allogeneic, “off-the-shelf” product that can be given without the need for matching between the donor and the patient. Additionally, Pluristem has been able to choose the appropriate dose of PLX-PAD to move commercialization of the product forward.” About Pluristem Pluristem is a clinical stage biotechnology company with patented technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem's proprietary and scalable PLX (PLacental eXpanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases. CLICK HERE to watch video clips in which CLI patients and doctors involved with the clinical trials share their stories. Safe Harbor Statement This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we are using forward looking statements when we say that data from clinical trials suggests that our placenta-derived cell therapy, PLX-PAD, is safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia, or that the statistically significant improvement in the symptom of pain as measured by the Visual Analogue Score (VAS) suggests PLX cells may be effective therapy for other pain syndromes, such as the neuropathic pain associated with Herpes Zoster (shingles), or that the previous announcement that PLX cells significantly improved the outcome in two different animal models of neuropathic pain in addition to the significant VAS improvement in this study suggests PLX cells may also be used as a potential pain therapy, or that the results of these trials provide a strong indication of the potential success of commercializing PLX-PAD, or that we have been able to choose the appropriate dose of PLX-PAD to move commercialization of the product forward. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching our clinical trials; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
For more information visit our Web site at www.pluristem.com, the content of which is not part of this press release.